Frenkel Catherine H, Donahue Erin E, Cochran Allyson, Brickman Daniel, Hong Steven, Ward Matthew C, Moeller Benjamin J, Carrizosa Daniel R, Milas Zvonimir L
Division of Surgical Oncology, Department of Surgery, Levine Cancer Institute, Atrium Health, Charlotte, North Carolina, USA.
Department of Cancer Biostatistics, Levine Cancer Institute, Atrium Health, Charlotte, North Carolina, USA.
Head Neck. 2025 Jan;47(1):68-80. doi: 10.1002/hed.27890. Epub 2024 Jul 28.
The Commission on Cancer (CoC) recently introduced a quality metric to optimize time between major head and neck surgery and adjuvant treatment (TAT) ≤6 weeks, as TAT delay adversely impacts patient survival. This study evaluates whether enhanced recovery after surgery (ERAS) for this population reduces the rate of postoperative complications, length of stay (LOS), and TAT.
Patients undergoing larynx or oral cavity resection with free flap reconstruction, ERAS, and adjuvant treatment after 2018 were compared to a historical pre-ERAS cohort. Patients underwent surgery at a single-institution tertiary referral center for complex head and neck oncology. Differences between groups were compared by chi-square, Fisher's exact, or Wilcoxon rank-sum test. TAT >6 weeks was evaluated with univariate and multivariable logistic regression.
Thirty-nine pre-ERAS patients were compared to 39 ERAS patients. No demographic differences existed between groups. LOS was improved with ERAS (p = 0.005). ERAS patients were discharged to home and returned to their activities of daily living (ADL) earlier (p = 0.004, 0.001). ADL recovery was associated with on-time TAT ≤42 days on univariate analysis (OR 1.36, 95% CI 1.13-1.63, p = 0.001). TAT delay was less frequent with ERAS (51.3% vs. 69.2%), but this was not significant after multivariable logistic regression (p = 0.11).
ERAS decreases LOS and returns advanced head and neck cancer patients to their ADL sooner. Postoperative ADL recovery independently predicts on-time adjuvant treatment. Still, compliance beyond 50% with the TAT ≤6 weeks CoC quality metric remains a major treatment barrier.
癌症委员会(CoC)最近引入了一项质量指标,以优化头颈部大手术与辅助治疗之间的时间间隔(TAT)≤6周,因为TAT延迟会对患者生存产生不利影响。本研究评估该人群的术后加速康复(ERAS)是否能降低术后并发症发生率、住院时间(LOS)和TAT。
将2018年后接受喉或口腔切除并游离皮瓣重建、ERAS及辅助治疗的患者与ERAS实施前的历史队列进行比较。患者在单一机构的三级转诊中心接受复杂头颈部肿瘤手术。组间差异采用卡方检验、Fisher精确检验或Wilcoxon秩和检验进行比较。对TAT>6周进行单因素和多因素逻辑回归分析。
将39例ERAS实施前患者与39例ERAS患者进行比较。两组间在人口统计学上无差异。ERAS使LOS得到改善(p = 0.005)。ERAS患者更早出院回家并恢复日常生活活动(ADL)(p = 0.004,0.001)。单因素分析显示,ADL恢复与TAT≤42天按时进行相关(OR 1.36,95%CI 1.13 - 1.63,p = 0.001)。ERAS组TAT延迟的情况较少(51.3%对69.2%),但多因素逻辑回归分析后差异无统计学意义(p = 0.11)。
ERAS可缩短LOS,并使晚期头颈部癌症患者更快恢复ADL。术后ADL恢复可独立预测按时进行辅助治疗。然而,TAT≤6周的CoC质量指标达标率超过50%仍是主要的治疗障碍。